{"id":"W4402565510","doi":"10.1016/j.annonc.2024.08.2291","title":"LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Eli Lilly Japan; MSD K.K.; Chugai Pharmaceutical; Novartis Pharma; University of Texas MD Anderson Cancer Center; EMD Serono; Bristol-Myers Squibb; Samsung; Genentech; European Society for Medical Oncology; Seagen; Pfizer; Moderna; Mirati Therapeutics; Les Laboratories Pierre Fabre; Eli Lilly and Company; Ono Pharmaceutical; Jazz Pharmaceuticals; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Regeneron Pharmaceuticals; AstraZeneca; American Society of Clinical Oncology; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Spectrum Pharmaceuticals; Amgen; Takeda Pharmaceutical Company","keywords":"Medicine; Nivolumab; Internal medicine; Perioperative; Placebo; Oncology; Phases of clinical research; Clinical trial; Surgery; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001449779,0.0006543741,0.002137268,0.0003754445,0.0002023047,0.001398,0.0007347791,0.00067152,0.002978831],"category_scores_gemma":[0.001654116,0.0003572915,0.001838611,0.0004959509,0.0003926524,0.0007782873,0.0003144365,0.002450536,0.0009511231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008943595,"about_ca_system_score_gemma":0.0007862041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001438,"about_ca_topic_score_gemma":0.006090674,"domain_scores_codex":[0.9997404,0.00009334783,0.00002407412,0.00004116208,0.00005119367,0.00004969414],"domain_scores_gemma":[0.9994054,0.0002342331,0.0001471102,0.00003388887,0.00006736104,0.0001120313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1640391,0.003378249,0.01615638,0.007073071,0.007091085,0.00018047,0.0002244268,0.002516231,0.0167122,0.001028253,0.03827982,0.7433208],"study_design_scores_gemma":[0.4987661,0.1604357,0.1405354,0.00381572,0.01810802,0.00174376,0.0004269287,0.004772899,0.007399725,0.00313205,0.1605871,0.0002764958],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7224848,0.2440891,0.001831076,0.005251864,0.002065379,0.001372645,0.00703765,0.0004761108,0.01539131],"genre_scores_gemma":[0.8719715,0.09390097,0.003407516,0.009925861,0.001192328,0.001417326,0.01174666,0.0001484878,0.006289319],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002978831,"threshold_uncertainty_score":0.009965181,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0800987718462758,"score_gpt":0.4419601438736218,"score_spread":0.361861372027346,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}